Search
INM005
go.drugbank.com/drugs/DB16499InvestigationalINM005 was under investigation in clinical trials for the treatment of COVID-19. It was studied for pharmacokinetics, efficacy, and safety in a completed trial (NCT04494984).
Thiamylal
go.drugbank.com/drugs/DB01154ApprovedVet approved(From Martindale, The Extra Pharmacopoeia, 30th ed, p919)
Flufenamic acid
go.drugbank.com/drugs/DB02266ApprovedIt is used in musculoskeletal and joint disorders and administered by mouth and topically. (From Martindale, The Extra Pharmacopoeia, 30th ed, p16)
Rubella virus vaccine
go.drugbank.com/drugs/DB10317ApprovedInvestigationalIt is prepared from RA 27/3 strain of live attenuated rubella virus. Rubella is a common childhood disease, caused by rubella virus (togavirus).
Benziodarone
go.drugbank.com/drugs/DB13277ApprovedWithdrawnIt is used in the treatment of gout [A175630]. It was withdrawn from France markets and British markets due to its effects causing Jaundice in patients [T487, A175636].
Veligrotug
go.drugbank.com/drugs/DB18976Approved[L63798] Thyroid eye disease has historically been managed differently depending on whether it is caught in the active inflammatory phase or has become chronic - Viridian describes veligrotug-vvze as the … [L63798] Although its precise mechanism in thyroid eye disease has not been fully characterized, IGF-1R blockade reduces the proptosis and diplopia that define the condition.
Enalaprilat
go.drugbank.com/drugs/DB09477ApprovedInvestigationalEnalaprilat is poorly orally available and is therefore only available as an intravenous injection for the treatment of hypertension when oral therapy is not possible. … Enalaprilat was originally created to overcome the limitations of the first ACE inhibitor, captopril, which had numerous side effects and left a metallic taste in the mouth.
Revumenib
go.drugbank.com/drugs/DB18515ApprovedInvestigational[L51888] In October of 20225, it was approved for myeloid leukemia patients with nucleophosmin 1 (NPM1) mutations. [L54376] … It was approved by the FDA in November 2024 for the treatment of leukemia with KMT2A aberrations,[L51868,L51863] becoming the first menin inhibitor to receive FDA approval.
Fomepizole
go.drugbank.com/drugs/DB01213ApprovedVet approvedFomepizole is used as an antidote in confirmed or suspected methanol or ethylene glycol poisoning.